• Mubritinib (TAK 165): A Selective Mitochondrial Complex I...

  2026-03-24

  Mubritinib (TAK 165) stands out as a potent, selective inhibitor of mitochondrial electron transport chain complex I, uniquely effective against chemotherapy-resistant AML and KSHV-positive lymphoma. Versatile in both cancer and antiviral workflows, its robust selectivity, nanomolar potency, and well-defined protocols make it an indispensable tool for targeted therapy and mechanistic research. Discover how APExBIO’s Mubritinib empowers advanced experimental designs and troubleshooting.

• Mubritinib (TAK 165): Redefining Mitochondrial Complex I ...

  2026-03-23

  Explore Mubritinib (TAK 165) as a selective mitochondrial electron transport chain complex I inhibitor, with a unique focus on its mechanistic role in overcoming chemotherapy resistance in acute myeloid leukemia and primary effusion lymphoma. This in-depth analysis offers advanced insights for cancer biology and targeted therapy research.

• Mubritinib (TAK 165): Transforming Targeted Cancer Therap...

  2026-03-23

  Mubritinib (TAK 165) stands out as both a selective mitochondrial complex I inhibitor and a HER2/ErbB2 pathway modulator, enabling researchers to interrogate cancer metabolism and viral persistence with unmatched precision. Its selective cytotoxicity in chemotherapy-resistant AML and KSHV-positive lymphoma models, combined with robust in vitro and in vivo performance, positions Mubritinib as a foundational tool for advanced cancer biology and translational studies.

• Mubritinib (TAK 165): Unlocking OXPHOS Vulnerabilities in...

  2026-03-22

  Discover how Mubritinib (TAK 165), a potent mitochondrial electron transport chain complex I inhibitor, is transforming acute myeloid leukemia research. This in-depth analysis explores its unique mechanisms, advanced applications, and the evolving landscape of targeted cancer therapy.

• Mubritinib (TAK 165): Advanced Workflows in Cancer and Vi...

  2026-03-21

  Mubritinib (TAK 165) is redefining targeted cancer therapy research by combining potent mitochondrial electron transport chain complex I inhibition with selective action in chemotherapy-resistant cancers and viral models. This guide delivers actionable workflows, real-world troubleshooting, and strategic insights on harnessing Mubritinib’s dual mechanism for robust, reproducible results.

• Mubritinib (TAK 165): Complex I Inhibition for AML and Ca...

  2026-03-20

  Mubritinib (TAK 165) is a next-generation selective inhibitor of mitochondrial complex I, enabling precise interrogation of oxidative phosphorylation and apoptosis in chemotherapy-resistant AML and KSHV-positive lymphoma. Unlike classic HER2 inhibitors, Mubritinib’s clinically relevant activity disrupts cancer cell metabolism with subtype selectivity, sparing normal cells for advanced targeted therapy research.

• Mubritinib (TAK 165): Selective Complex I and HER2 Inhibi...

  2026-03-20

  Mubritinib (TAK 165) is a potent inhibitor of mitochondrial complex I and a selective HER2/ErbB2 inhibitor. It demonstrates strong cytotoxicity against chemotherapy-resistant AML and KSHV-positive PEL cells, with high selectivity and validated protocols for in vitro and in vivo research. APExBIO provides Mubritinib (SKU B1543) as a rigorously qualified tool compound for targeted cancer therapy research.

• Mubritinib (TAK 165): Redefining Mitochondrial Inhibition...

  2026-03-19

  Explore the unique capabilities of Mubritinib (TAK 165) as a selective mitochondrial electron transport chain complex I inhibitor for advanced cancer biology and virology research. This article delivers a deep-dive analysis, mechanistic clarity, and practical guidance that goes beyond traditional HER2 inhibitor narratives.

• Mubritinib (TAK 165): Mitochondrial Complex I Inhibition ...

  2026-03-19

  Explore the unique dual action of Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor and antiviral agent. This in-depth article unveils advanced mechanistic insights, clinical implications beyond HER2 inhibition, and new avenues for targeted cancer therapy research.

• Mubritinib (TAK 165): A Selective Mitochondrial Complex I...

  2026-03-18

  Mubritinib (TAK 165) stands apart as both a mitochondrial electron transport chain complex I inhibitor and a selective HER2 pathway modulator, uniquely targeting chemotherapy-resistant AML and viral-driven cancers. This guide details optimized protocols, advanced experimental use-cases, and troubleshooting strategies to unlock Mubritinib’s full research potential.

• Mubritinib (TAK 165): Precision in OXPHOS Inhibition for ...

  2026-03-18

  This article provides evidence-based guidance for deploying Mubritinib (TAK 165, SKU B1543) in cell viability and cytotoxicity workflows, focusing on experimental design, reproducibility, and data interpretation in acute myeloid leukemia and primary effusion lymphoma research. Integrating scenario-driven Q&A, it supports scientists in choosing and optimizing mitochondrial complex I inhibition assays with validated protocols and comparative vendor insights.

• Mubritinib (TAK 165): From HER2 Inhibitor to Mitochondria...

  2026-03-17

  A comprehensive, thought-leadership article for translational researchers, examining the mechanistic, experimental, and strategic landscape of Mubritinib (TAK 165). This piece explores Mubritinib’s evolution from a selective HER2 inhibitor to a cutting-edge mitochondrial electron transport chain complex I inhibitor, contextualizing its role in chemotherapy-resistant acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) research, as well as its antiviral potential. Integrating insights from contemporary Alzheimer’s disease research and highlighting the innovative edge provided by APExBIO’s Mubritinib, the article offers actionable guidance for optimizing translational workflows and conceptualizing future directions.

• Mubritinib (TAK 165) in Cancer and Viability Assays: Data...

  2026-03-17

  This article provides an evidence-based, scenario-focused roadmap for researchers leveraging Mubritinib (TAK 165), SKU B1543, in cell viability and targeted cancer biology workflows. Drawing on peer-reviewed data and real laboratory challenges, we illustrate how APExBIO’s Mubritinib delivers selective, reproducible results in complex I inhibition, AML, and PEL research while supporting reliable assay performance.

• Mubritinib (TAK 165): Advanced Insights in Mitochondrial ...

  2026-03-16

  Explore Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor with unique roles in cancer biology and antiviral research. This in-depth review uncovers mechanistic nuances and new translational strategies, setting it apart from typical protocol-driven guides.

• Mubritinib (TAK 165): Mitochondrial Complex I Inhibition ...

  2026-03-16

  Explore Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor, with unique antiviral and antileukemic mechanisms. This in-depth article reveals novel insights beyond HER2 inhibition, advancing selective cancer therapy research.

455 records 24/31 page Previous Next First page 上5页 2122232425 下5页 Last page